BWI: Sun Pharma Announces USFDA Approval for Generic Clarinex®

Press release from Business Wire India
Source: Sun Pharmaceuticals Industries Ltd
Thursday, November 18, 2010 01:23 PM IST (07:53 AM GMT)
Editors: General: Consumer interest; Business: Advertising, PR & marketing, Business services, Healthcare, biotechnology & pharmaceutical; Healthcare
--------------------------------------------------
Sun Pharma Announces USFDA Approval for Generic Clarinex®


Mumbai, Maharashtra, India, Thursday, November 18, 2010 -- (Business Wire India) -- Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) announced that USFDA has granted it an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Schering Plough's Clarinex® tablets, 5 mg.

These generic Clarinex tablets contain desloratidine 5 mg and are therapeutically equivalent to Schering Plough's Clarinex tablets 5mg.

Generic Clarinex tablets are indicated in the treatment of seasonal allergic rhinitis, perennial allergic rhinitis and Chronic idiopathic urticaria.

This strength of Clarinex® has annual sales of approximately $ 212 million in the US.

® Registered trademark of Schering Corp., a subsidiary of Merck & Co., Inc.

About Sun Pharmaceutical Industries Ltd.

Established in 1983, listed since 1994 and headquartered in India, Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, orthopedics and ophthalmology. The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms. More information about the company can be found at www.sunpharma.com.


CONTACT DETAILS
Uday Baldota, Sun Pharmaceuticals Industries Ltd, +91 22 6645 5645, Xtn 605/ +91 9867010529, uday.baldota@sunpharma.com
Mira Desai, Sun Pharmaceuticals Industries Ltd, +91 22 6645 5645, Xtn 606/ +91 9821923797, mira.desai@sunpharma.com

KEYWORDS
CONSUMER, MARKETING, BUSINESS SERVICES, HEALTHCARE, HEALTHCARE

If you wish to change your Business Wire India selection please click on this link http://www.businesswireindia.com/media/news.asp and use your personal username and password to login.

Submit your press release at http://www.businesswireindia.com